Published in Blood on October 01, 1984
Elevated factor Xa activity in the blood of asymptomatic patients with congenital antithrombin deficiency. J Clin Invest (1985) 0.94
Changes in amniotic fluid concentration of thrombin-antithrombin III complexes in patients with preterm labor: evidence of an increased thrombin generation. J Matern Fetal Neonatal Med (2009) 0.84
Pathogenesis and treatment of thrombohemorrhagic diathesis in acute promyelocytic leukemia. Mediterr J Hematol Infect Dis (2011) 0.84
Laboratory Measurement of Thrombin Activity--What Every Clinician Scientist Needs to Know. J Thromb Thrombolysis (1995) 0.79
Abnormal factor VIII coagulant antigen in patients with renal dysfunction and in those with disseminated intravascular coagulation. J Clin Invest (1985) 0.75
Thrombophilia: how far should a clotter be investigated? Postgrad Med J (1994) 0.75
Breast Cancer Surveillance Consortium: a national mammography screening and outcomes database. AJR Am J Roentgenol (1997) 7.62
A novel role for 3-O-sulfated heparan sulfate in herpes simplex virus 1 entry. Cell (1999) 6.82
Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA (2005) 5.60
Targeted disruption of cd39/ATP diphosphohydrolase results in disordered hemostasis and thromboregulation. Nat Med (1999) 4.44
Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. N Engl J Med (2001) 4.33
The purification and mechanism of action of human antithrombin-heparin cofactor. J Biol Chem (1973) 4.24
Brief report: variability of thrombosis among homozygous siblings with resistance to activated protein C due to an Arg-->Gln mutation in the gene for factor V. N Engl J Med (1994) 4.00
The Emerging Risk Factors Collaboration: analysis of individual data on lipid, inflammatory and other markers in over 1.1 million participants in 104 prospective studies of cardiovascular diseases. Eur J Epidemiol (2007) 3.81
The separation of active and inactive forms of heparin. Biochem Biophys Res Commun (1976) 2.91
Activation of coagulation after administration of tumor necrosis factor to normal subjects. N Engl J Med (1990) 2.82
Antisense c-myb oligonucleotides inhibit intimal arterial smooth muscle cell accumulation in vivo. Nature (1992) 2.73
Benefits versus risks from mammography: a critical reassessment. Cancer (1996) 2.43
Anticoagulant action of heparin. Nature (1973) 2.26
Isolation of a src homology 2-containing tyrosine phosphatase. Proc Natl Acad Sci U S A (1992) 2.22
A targeted point mutation in thrombomodulin generates viable mice with a prethrombotic state. J Clin Invest (1998) 2.08
Actions and interactions of antithrombin and heparin. N Engl J Med (1975) 2.06
Current medicolegal and confidentiality issues in large, multicenter research programs. Am J Epidemiol (2000) 2.06
Thrombosis and ELISA optical density values in hospitalized patients with heparin-induced thrombocytopenia. J Thromb Haemost (2004) 2.04
Cloned bovine aortic endothelial cells synthesize anticoagulantly active heparan sulfate proteoglycan. J Biol Chem (1986) 2.02
Inherited thrombophilia: Part 1. Thromb Haemost (1996) 2.00
Inhibition of rat arterial smooth muscle cell proliferation by heparin. In vivo studies with anticoagulant and nonanticoagulant heparin. Circ Res (1980) 2.00
Inhibition of vascular smooth muscle cell growth by endothelial cell-derived heparin. Possible role of a platelet endoglycosidase. J Biol Chem (1982) 1.99
Isolation and characterization of endothelial progenitor cells from mouse embryos. Development (1998) 1.94
Increased incidence of neoplasia of the digestive tract in men with persistent activation of the coagulant pathway. J Thromb Haemost (2004) 1.91
Mast cell clones: a model for the analysis of cellular maturation. J Cell Biol (1982) 1.91
PR39, a peptide regulator of angiogenesis. Nat Med (2000) 1.90
Contribution of monosaccharide residues in heparin binding to antithrombin III. Biochemistry (1985) 1.89
Chemistry of the hemostatic mechanism and its relationship to the action of heparin. Fed Proc (1977) 1.83
Correlation between structure and function of heparin. Proc Natl Acad Sci U S A (1979) 1.83
An antiproliferative heparan sulfate species produced by postconfluent smooth muscle cells. J Cell Biol (1985) 1.83
Molecular heterogeneity of inherited antithrombin III deficiency. N Engl J Med (1983) 1.75
Natural anticoagulant mechanisms. J Clin Invest (1984) 1.75
Vascular bed-specific expression of an endothelial cell gene is programmed by the tissue microenvironment. J Cell Biol (1997) 1.74
Anticoagulantly active heparin-like molecules from vascular tissue. Biochemistry (1984) 1.70
Relationship between markers of activated coagulation, their correlation with inflammation, and association with coronary heart disease (NPHSII). J Thromb Haemost (2007) 1.67
Structure-function relationships of heparin species. Proc Natl Acad Sci U S A (1978) 1.65
D-dimer, factor VIII coagulant activity, low-intensity warfarin and the risk of recurrent venous thromboembolism. J Thromb Haemost (2006) 1.62
BAY 59-7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study. J Thromb Haemost (2005) 1.60
Expression of heparan sulfate D-glucosaminyl 3-O-sulfotransferase isoforms reveals novel substrate specificities. J Biol Chem (1999) 1.58
Spontaneous thrombosis in mice carrying the factor V Leiden mutation. Blood (2000) 1.58
Multiple isoforms of heparan sulfate D-glucosaminyl 3-O-sulfotransferase. Isolation, characterization, and expression of human cdnas and identification of distinct genomic loci. J Biol Chem (1999) 1.58
Absence of the blood-clotting regulator thrombomodulin causes embryonic lethality in mice before development of a functional cardiovascular system. Proc Natl Acad Sci U S A (1995) 1.58
Inhibition of activated factor XII by antithrombin-heparin cofactor. J Biol Chem (1976) 1.56
Heparinlike molecules with anticoagulant activity are synthesized by cultured endothelial cells. Biochem Biophys Res Commun (1985) 1.56
Treatment of coumarin-induced skin necrosis with a monoclonal antibody purified protein C concentrate. Arch Dermatol (1993) 1.55
Enzymatic modification of heparan sulfate on a biochip promotes its interaction with antithrombin III. Biochem Biophys Res Commun (2000) 1.51
Inhibition of endotoxin-induced activation of coagulation and fibrinolysis by pentoxifylline or by a monoclonal anti-tissue factor antibody in chimpanzees. J Clin Invest (1994) 1.50
Acceleration of thrombin-antithrombin complex formation in rat hindquarters via heparinlike molecules bound to the endothelium. J Clin Invest (1984) 1.48
Haemostatic changes that constitute the hypercoagulable state. Lancet (1991) 1.47
The kinetics of hemostatic enzyme-antithrombin interactions in the presence of low molecular weight heparin. J Biol Chem (1980) 1.47
Isolation and characterization of heparin from human lung. J Clin Invest (1979) 1.46
Heparan sulfate D-glucosaminyl 3-O-sulfotransferase-3A sulfates N-unsubstituted glucosamine residues. J Biol Chem (1999) 1.45
Multiple functional domains of the heparin molecule. Proc Natl Acad Sci U S A (1981) 1.45
Tumor necrosis factor suppresses transcription of the thrombomodulin gene in endothelial cells. Mol Cell Biol (1988) 1.44
Purification and properties of human platelet heparitinase. J Biol Chem (1982) 1.42
Effect of heparin and heparin fractions on platelet aggregation. J Clin Invest (1980) 1.42
Molecular cloning and expression of two distinct cDNA-encoding heparan sulfate proteoglycan core proteins from a rat endothelial cell line. J Biol Chem (1992) 1.41
Localization of anticoagulantly active heparan sulfate proteoglycans in vascular endothelium: antithrombin binding on cultured endothelial cells and perfused rat aorta. J Cell Biol (1990) 1.40
Characterization of two naturally occurring mutations in the second epidermal growth factor-like domain of factor VII. Blood (1999) 1.40
Biologic actions of heparin. Semin Hematol (1977) 1.38
The purification of megapoietin: a physiological regulator of megakaryocyte growth and platelet production. Proc Natl Acad Sci U S A (1994) 1.36
The reciprocal relationship of thrombopoietin (c-Mpl ligand) to changes in the platelet mass during busulfan-induced thrombocytopenia in the rabbit. Blood (1995) 1.35
Microvascular heparin-like species with anticoagulant activity. Am J Physiol (1983) 1.34
Inherited thrombophilia: Part 2. Thromb Haemost (1996) 1.34
Binding of lipoprotein lipase to endothelial cells in culture. J Biol Chem (1981) 1.31
The pathophysiology of the prethrombotic state in humans: insights gained from studies using markers of hemostatic system activation. Blood (1987) 1.31
Improvement in mammography interpretation skills in a community radiology practice after dedicated teaching courses: 2-year medical audit of 38,633 cases. Radiology (1992) 1.30
Molecular cloning and expression of mouse and human cDNAs encoding heparan sulfate D-glucosaminyl 3-O-sulfotransferase. J Biol Chem (1997) 1.30
Structural determinants of the capacity of heparin to inhibit the proliferation of vascular smooth muscle cells. J Cell Physiol (1984) 1.29
Structure of the rat platelet factor 4 gene: a marker for megakaryocyte differentiation. Mol Cell Biol (1987) 1.29
Transcriptional regulation of the rat platelet factor 4 gene: interaction between an enhancer/silencer domain and the GATA site. Mol Cell Biol (1991) 1.28
Persistent activation of coagulation mechanism in unstable angina and myocardial infarction. Circulation (1994) 1.28
Systematically missing confounders in individual participant data meta-analysis of observational cohort studies. Stat Med (2009) 1.27
The clinical spectrum of heterozygous protein C deficiency in a large New England kindred. Blood (1989) 1.26
Enhancement of murine cardiac chronotropy by the molecular transfer of the human beta2 adrenergic receptor cDNA. J Clin Invest (1998) 1.25
Heparin with two binding sites for antithrombin or platelet factor 4. J Biol Chem (1982) 1.25
Inhibition of human factor IXa by human antithrombin. J Biol Chem (1975) 1.25
Selective targeting of gene products with the megakaryocyte platelet factor 4 promoter. Proc Natl Acad Sci U S A (1991) 1.24
Studies of the prothrombin activation pathway utilizing radioimmunoassays for the F2/F1 + 2 fragment and thrombin--antithrombin complex. Blood (1982) 1.24
Structural determinants of the capacity of heparin to inhibit the formation of the human amplification C3 convertase. J Clin Invest (1981) 1.23
The effects of quality and timing of venepuncture on markers of blood coagulation in healthy middle-aged men. Thromb Haemost (1995) 1.23
6-O-sulfotransferase-1 represents a critical enzyme in the anticoagulant heparan sulfate biosynthetic pathway. J Biol Chem (2001) 1.23
Endothelial expression of thrombomodulin is reversibly regulated by fluid shear stress. Circ Res (1994) 1.22
Human von Willebrand factor gene sequences target expression to a subpopulation of endothelial cells in transgenic mice. Proc Natl Acad Sci U S A (1995) 1.20
Respiratory muscle strength in congestive heart failure. Chest (1990) 1.20
Expression cloning of LDLB, a gene essential for normal Golgi function and assembly of the ldlCp complex. Proc Natl Acad Sci U S A (1999) 1.20
Acute aortic thrombosis in antithrombin III deficiency. JAMA (1981) 1.20